NEWS
‘The Price of Business’: A Major Fiscal Crisis is Brewing and Largely Ignored by the Media
Alex Brill joined Kevin Price on ‘The Price of Business’ to discuss the fact that the US will add over $1 trillion to the deficit in a single year.
1 big thing: Congress takes on PBMs
“Alex Brill, CEO of the economic consulting firm Matrix Global Advisors and a senior fellow at AEI, said it is “unnecessary” to require PBMs to pass the rebates along to plans.”
Here comes Humira competition
MGA’s analysis of the competition as new adalimumab biosimilars enter market.
Humira Competitors Don’t Guarantee Lower Patient Drug Costs
“The launches this month are “more of an inflection point in the market compared to what we saw in January when Amjevita came to market,” said Alex Brill.
The State of Biosimilars: What to Watch
Now that biosimilar versions of Humira are starting to arrive, what happens next? Will this finally prove the case that biosimilars can deliver on big health care savings?
‘The Price of Business’: Discussing the Latest Inflation Report
On July 12, Alex Brill joined Kevin Price on ‘The Price of Business’ to discuss the latest inflation report. What could be behind the significant drop?
Alex Brill Interviewed on the Future of the Adalimumab Market
MGA’s Alex Brill was interviewed by Mari Serebvrov for a new piece in BioWorld to discuss the latest with the adalimumab market as new competition is expected as early as July 1.
Taking Stock of the Humira Biosimilars Market
In January, the 21-year monopoly for AbbVie’s blockbuster drug Humira (adalimumab) came to an end with the launch of Amjevita, Amgen’s biosimilar adalimumab.
MGA’s Alex Brill on CNBC’s Squawk Box Discussing House Republican tax proposals
Alex Brill joined CNBC’s Squawk Box to discuss Biden’s billionaire tax policy proposal and why it is not desirable for the U.S. economy.
Analyzing the Build It in America Act: Proposals for Business Tax Reform
Last week, the House Committee on Ways and Means released three tax bills, and this week the Committee will meet to consider these measures.
MGA’s Latest: A Look at Community Health Centers
MGA’s state-by-state analysis of Community Health Centers’ economic impact.
Flawed Approach: The Working Families Tax Cut Act as a Response to Inflation
Earlier this week, Congresswomen Nicole Malliotakis (R-NY) and Michelle Steel (R-CA), who are both members of the House Committee on Ways and Means, introduced the Working Families Tax Cut Act.
PBM Concerns Induce Surprising Bipartisanship
Recent congressional focus on the business practices of pharmacy benefit managers (PBMs) has been intense. Six committees have held 11 hearings related to PBMs in the first 20 weeks of the 118th Congress, and legislation is advancing in both chambers.
MGA’s Latest Work Examining Digital Health Tools
MGA has released a new report today for the Coalition for Affordable Prescription Drugs (CAPD), “Patent Thickets and Lost Drug Savings.”
‘The Price of Business’: Discussing the Debt Crisis
‘The Price of Business’: Discussing the Future of Working at Home
On April 13, Alex Brill joined Kevin Price on ‘The Price of Business’ discussing the future of working from home.
Listen here. Other interviews with Kevin Price can be found here, here and here.
- ‘The Price of Business’: A Major Fiscal Crisis is Brewing and Largely Ignored by the Media
- 1 big thing: Congress takes on PBMs
- Here comes Humira competition
- Humira Competitors Don’t Guarantee Lower Patient Drug Costs
- The State of Biosimilars: What to Watch
- ‘The Price of Business’: Discussing the Latest Inflation Report
- Alex Brill Interviewed on the Future of the Adalimumab Market
- Taking Stock of the Humira Biosimilars Market
- MGA’s Alex Brill on CNBC’s Squawk Box Discussing House Republican tax proposals
- Analyzing the Build It in America Act: Proposals for Business Tax Reform
